Reduced serum level of antibodies against amyloid beta peptide is associated with aging in Tg2576 mice.

Biochem Biophys Res Commun

Department of Biochemistry and Cancer Research Institute, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul 110-799, Republic of Korea.

Published: September 2007

Both active and passive immunization to eliminate amyloid plaques from the brain of patients with Alzheimer's disease (AD) have confirmed that amyloid beta (Abeta) vaccination does not only result in clearance of Abeta plaques but improves behavioral-cognitive deficits in animal models of AD. In the present study, the levels of naturally occurring serum antibodies against Abeta were measured in Tg2576 mice at various ages using ELISA to determine the relationship between aging and the level of anti-Abeta autoantibody. The level of anti-Abeta antibody fell significantly at the age of 9 months, at the age when amyloid plaques started to appear in the brain of Tg2576 mice, and was persistently low thereafter. However, serum immunoglobulin (Ig) level was elevated in older transgenic mice compared with younger transgenic mice suggesting that the reduced level of anti-Abeta autoantibody was not merely due to deterioration of the immune response in aged Tg2576 mice.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2007.07.107DOI Listing

Publication Analysis

Top Keywords

tg2576 mice
16
level anti-abeta
12
amyloid beta
8
amyloid plaques
8
anti-abeta autoantibody
8
transgenic mice
8
mice
6
level
5
reduced serum
4
serum level
4

Similar Publications

Background: Recent studies have identified hearing loss (HL) as a primary risk factor for Alzheimer's disease (AD) onset. However, the mechanisms linking HL to AD are not fully understood. This study explored the effects of drug-induced hearing loss (DIHL) on the expression of proteins associated with AD progression in mouse models.

View Article and Find Full Text PDF

Gut microbiota dysbiosis in Alzheimer's disease (AD): Insights from human clinical studies and the mouse AD models.

Physiol Behav

December 2024

Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA, USA; Deptment of Neuroscience & Regenerative Medicine, Augusta, GA 30912, USA; College of Agriculture, Food, and Natural Resources, Prairie View A&M University, Prairie View, TX 77446, USA; Centre for Healthy Aging, Medical College of Georgia, Augusta University, Augusta, GA, USA; Department of Cell Biology and Anatomy, Medical College of Georgia, Augusta University, GA, USA; Department of Orthopedic Surgery, Medical College of Georgia, Augusta University, Augusta, GA, USA. Electronic address:

Alzheimer's Disease (AD) is a debilitating neurocognitive disorder with an unclear underlying mechanism. Recent studies have implicated gut microbiota dysbiosis with the onset and progression of AD. The connection between gut microbiota and AD can significantly affect the prevention and treatment of AD patients.

View Article and Find Full Text PDF
Article Synopsis
  • Endocannabinoids show promise in reducing neuroinflammation related to Alzheimer's disease (AD) by potentially rebalancing autophagic mechanisms.
  • Researchers administered URB597, an FAAH inhibitor that increases anandamide levels, to both microglial cultures and Tg2576 transgenic mice.
  • The treatment led to a shift in microglia toward an anti-inflammatory state, reduced amyloid plaque formation, and restored key autophagy markers, indicating a possible therapeutic approach for AD.
View Article and Find Full Text PDF

Extra-cerebral manifestations of Alzheimer's disease (AD) develop in the retina, which is, therefore, considered a "window to the brain". Recent studies demonstrated the dysregulation of the endocannabinoid (eCB) system (ECS) in AD brain. Here, we explored the possible alterations of ECS and the onset of gliosis in the retina of AD-like mice.

View Article and Find Full Text PDF

mCLAS adaptively rescues disease-specific sleep and wake phenotypes in neurodegeneration.

Sleep Med

December 2024

Department of Neurology, University Hospital Zurich (USZ), Switzerland; Neuroscience Center Zurich (ZNZ), Switzerland; Center of Competence Sleep and Health, University of Zurich (UZH), Switzerland. Electronic address:

Article Synopsis
  • Sleep changes are common in Alzheimer's and Parkinson's diseases, affecting brain health during deep sleep.
  • A new method called mouse closed-loop auditory stimulation (mCLAS) has been developed to enhance slow-wave activity during deep sleep in models of these diseases.
  • Initial findings show that mCLAS can improve sleep patterns in mice, with different effects seen in Alzheimer's versus Parkinson's models, suggesting potential for future sleep-based therapies in neurodegenerative conditions.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!